This study aimed to determine fibulin-3 levels in plasma of patients with MM before treatment and in various responses to treatment (complete response, partial response, stable disease, and progressive disease), to evaluate its potential applicability as a biomarker of tumour response to treatment, and to assess if plasma level of fibulin-3 could predict the probability of progressive disease after the response to treatment in the period of 18 months. This evidence concerns the gene EFEMP1 and neoplasm.